Sun Pharma notes Organon shareholder approval for proposed acquisition
The shareholder approval marks an important milestone towards completion of the proposed transaction.
Sun Pharmaceutical Industries announced that the stockholders of Organon have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, an indirect wholly owned subsidiary of Sun Pharma.
The shareholder approval marks an important milestone towards completion of the proposed transaction.
The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals. For additional information regarding the proposed transaction, please refer to Sun Pharma’s announcement dated April 27, 2026.